Clinical trial
French Assessment of Minimal Residual Disease by Liquid Biopsies in Stage III Colorectal Patients
NCT06287814 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- French Assessment of Minimal Residual Disease by Liquid Biopsies in Stage III Colorectal Patients
- Lead sponsor
- University Hospital, Montpellier
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- April 11, 2024
- Completion date
- October 31, 2033
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer, liquid biopsy, minimal residual disease, stage iii colon cancer